Addus HomeCare Corporation (ADUS) Stock Price & Analysis

Addus HomeCare Corporation (ADUS) closed at USD 122.67 on Thursday, October 22, 2026, up 4.00% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 117.95; the Oct 22, 2026 session ranged USD 118.38–123.19 on volume of 147,467 shares. Market capitalization is $2.29B, with a 52-week range of USD 87.95–124.44 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ADUS.md

Key facts (ADUS)

• Last four reported quarters (through Jun 30, 2026): revenue $1.48B, net income $105M (7.1% margin), free cash flow $155M (SEC filings).
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $90K; 2 not under a Rule 10b5-1 plan ($47K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Total return with dividends: 1Y +1.6% vs S&P 500 +14.9%; 5Y +49.6% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD 1.79, revenue estimate $389M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ADUS)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ADUS)

P/E at fiscal year-ends: Dec 2025 20.6x, Dec 2024 29.6x, Dec 2023 24.2x.

Insider sales (SEC Form 4, open-market, last ~7 months) (ADUS)

2 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ADUS)

Rating changes, last 120 days:

Total return (dividends reinvested) (ADUS)

ADUS revenue by business segment (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ADUS suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

ADUS company outlook (results filed Aug 3, 2026)

• “By delivering a full continuum of care as we scale, we anticipate acting on meaningful synergies and uncovering further growth opportunities throughout the remainder of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

ADUS analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 10:01 UTC)

Technical Analysis (ADUS)

Nexqual's technical model rates ADUS "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.

Earnings (ADUS)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:01 UTC.

Financials & Fundamentals (ADUS)

Source: Nexqual, October 23, 2026 at 10:01 UTC.

Ownership (ADUS)

Source: Nexqual, October 23, 2026 at 10:01 UTC.

From Addus HomeCare Corporation's Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• For financial management, we utilize Oracle's Planning Budgeting Cloud Service as our solution for budgeting, forecasting, and financial reporting and Oracle Fusion for the general ledger, accounts payable and fixed assets.
• In particular, the demand for personal care services is growing from managed care delivery models, including Medicaid Long-Term Services and Supports programs and Medicare Advantage plans.
• We believe that our personal care program and our technology make us well-suited to partner with managed care organizations to address the needs of the dual-eligible population, and we believe that our ability to identify changes in our consumers' health and condition before acute intervention is required will lower the overall cost of care.

Legal & Regulatory Risks (Item 1A, quoted)

• Our hospice operations are subject to annual Medicare caps. If we exceed the caps, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.
• The implementation of alternative payment models and any increases in enrollment in Medicare Advantage or Medicaid managed care plans may limit our market share and could adversely affect our revenues.
• We may be similarly impacted by increases in enrollment of Medicare and Medicaid beneficiaries in managed care plans, which are part of the general shift away from traditional fee-for-service models.
• We are subject to federal, state and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt